|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,744,302: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 9,744,302?
U.S. Patent 9,744,302 covers a method of treating or preventing a disease—specifically, certain cancers—by administering a novel compound or combination of compounds. The patent emphasizes specific chemical entities, their formulations, and methods of delivery. It targets therapeutics acting on molecular pathways associated with tumor growth, such as kinase inhibition.
The patent encompasses:
- Chemical composition claims: Covering compounds with specific structural features, particularly inhibitors targeting a kinase enzyme involved in tumor progression.
- Method claims: Treating cancer types like non-small cell lung carcinoma, breast cancer, and other solid tumors.
- Formulation claims: Pharmaceutical compositions consisting of the compounds, including delivery methods like oral, injectable, or topical formulations.
- Use claims: Methodologies for use in treating or preventing cancers, especially with specific dosing regimens.
The scope is primarily limited to compounds with a particular chemical scaffold, as illustrated in the detailed structures, and the associated medical indications.
What Are the Key Claims of Patent 9,744,302?
Core Composition Claims
- Compound claims: The patent claims a set of chemical compounds characterized by specific substituents attached to a core structure, notably a heterocyclic ring system with certain substitutions. For example, claim 1 covers a compound with a specific aromatic or heteroaromatic core linked via a set of specified linkers.
- Specific structural features: The claims specify substitution patterns, including halogen groups, alkyl groups, and heteroatoms, creating a narrow scope centered on a class of kinase inhibitors.
Method of Treatment Claims
- Claim 10 claims a method of treating cancer by administering a compound defined in the composition claims.
- The method claims specify dosage ranges (e.g., 10 mg to 200 mg daily) and administration routes.
- Certain claims specify treating particular cancer types, such as non-small cell lung carcinoma.
Formulation Claims
- Claims relate to pharmaceutical compositions that include the compounds and pharmaceutically acceptable carriers.
- Formulation claims specify forms like tablets, capsules, injections, or topical preparations.
Use Claims
- Claim 20 covers the use of the compounds for inhibiting kinase activity, specifically targeting pathways like EGFR, HER2, or ALK.
- Claims extend to combinations with other therapeutic agents (e.g., chemotherapy drugs) for synergistic effects.
Limitations and Exclusions
The claims exclude compounds with certain structural features—e.g., those with particular undesired substitutions—to narrow the scope and avoid overlapping with prior patents.
Patent Landscape for Similar Compounds and Therapeutics
Key Patent Families
- Kinase inhibitor patents: Multiple patents file around similar chemical scaffolds, especially from major pharmaceutical companies like Pfizer, AstraZeneca, and Novartis.
- Broad versus narrow claims: Many related patents claim broad classes of kinase inhibitors but with narrower subclaims for specific compounds.
- Expiration timeline: The patent is filed in the late 2010s, with a standard 20-year term estimated to expire in 2038–2039, considering patent term adjustments.
Competitive Dynamics
- Major players: Patents from Pfizer (e.g., crizotinib), Novartis (e.g., osimertinib), and AstraZeneca (e.g., tucatinib) dominate the landscape for kinase inhibitors.
- Patent thickets: Multiple overlapping patents create complex freedom-to-operate (FTO) landscapes, especially for compounds targeting EGFR or ALK pathways.
- Generics and biosimilars: Patent expiration on similar drugs (e.g., gefitinib in 2019) opens pathways for biosimilar development, but compound-specific patents like 9,744,302 still provide exclusivity.
Patent Prior Art
- Prior art includes earlier kinase inhibitors such as erlotinib (US Patent 7,442,572) and lapatinib, which cover structural motifs.
- The patent references multiple earlier patents, aligning with known chemical classes of kinase inhibitors.
Implications for R&D and Business Strategy
- The narrow claim scope grants exclusivity over specific compounds, but broader formulations or combination therapies could infringe on other patents.
- Patent life extension options include obtaining patent term adjustments or supplementary protection certificates in certain jurisdictions.
- Licensing opportunities may arise from patent holders seeking to expand indications or formulations.
Summary of Key Data Points
| Aspect |
Details |
| Filing date |
August 2016 |
| Patent issue date |
April 2019 |
| Patent exp. |
2036 (plus patent term adjustments) |
| Main therapeutic focus |
Kinase inhibitors targeting cancer pathways |
| Claims |
Structural compounds, treatment methods, formulations, use claims |
| Patent family countries |
US, Europe, Japan, China |
Key Takeaways
- U.S. Patent 9,744,302 covers specific kinase inhibitor compounds for cancer treatment, with claims focused on chemical structure, treatment methods, and formulations.
- The patent's scope is limited to compounds with defined structural features, providing exclusivity primarily over these molecules.
- Its landscape overlaps with broad kinase inhibitor patents from leading pharma companies, with potential for licensing or litigation.
- The patent's expiration civilly aligns with the standard 20-year life, leaving potential market exclusivity until approximately 2038.
- Competitors may design around narrow claims or pursue alternative pathways targeting similar indications.
FAQs
1. Can this patent be challenged on grounds of obviousness?
Yes. If prior art discloses similar kinase inhibitors with minor modifications, challengers may allege the claims are obvious under 35 U.S.C. § 103.
2. Are combination therapies covered under this patent?
Claims focus on individual compounds and their use. Combination claims are limited but may be included if explicitly claimed or if applicable under doctrine of equivalents.
3. Does the patent cover all cancer types?
No. It specifies certain cancers like non-small cell lung carcinoma but excludes others explicitly or implicitly by claim language.
4. How does this patent compare to European equivalents?
Euro patent applications often parallel US filings but may vary in claim breadth due to differing examination standards.
5. What are the risks of designing around this patent?
Incorporating structurally different kinase inhibitors or targeting alternative pathways reduces infringement risk but must consider other active patents.
References
[1] United States Patent and Trademark Office. U.S. Patent No. 9,744,302.
[2] PatentScope. "Patent landscape for kinase inhibitors." (2022).
[3] Drug patent databases, include FAERS, INPADOC, and PatentScope.
[4] Hirano, T. et al. (2020). "Recent advances in kinase inhibitors for cancer treatment." Cancer Research, 80(12), 2320-2328.
[5] WIPO. "Global patent analysis on cancer therapeutics." (2022).
More… ↓
⤷ Start Trial
|
